体外研究 (In Vitro) |
Roburic acid (1-10 μM; 6 days) 可在骨髓巨噬细胞 (BMMs) 中抑制 RANKL 诱导的破骨细胞生成,其在早期阶段 (第 1-3 天) 的作用最强,且在测试浓度下无细胞毒性。 Roburic acid (10 μM; 7 days) 对 MC3T3-E1 细胞的成骨细胞分化无影响。 Roburic acid (5-10 μM) 可阻断 RANKL 诱导的骨髓巨噬细胞来源破骨细胞中 F-actin 环的形成。 Roburic acid (5-10 μM; 2 days) 可在骨髓巨噬细胞 (BMMs) 中抑制由 RANKL 诱导的破骨细胞骨吸收活性。 Roburic acid (5-10 μM; 6 days) 可在 RANKL 刺激的 BMM 中呈剂量依赖性地下调破骨细胞相关基因的表达。 Roburic acid (1-10 μM; 7 h) 可抑制 RAW264.7 细胞中由 RANKL 诱导的 NF-κB 活性。 Roburic acid (10 μM; 10 min-5 days) 可抑制 RANKL 诱导的 BMMs 中 TRAF6 表达、ERK 磷酸化及 IκB-α 降解。 Roburic acid (1-10 μM; 48 h) 以剂量依赖的方式增强 RAW264.7 细胞中被 RANKL 抑制的 Nrf2/ARE 活性。 Roburic acid (10 μM; 1-3 days) 上调 RANKL 刺激的骨髓巨噬细胞 (BMMs) 中 HO-1 蛋白的表达。 Roburic acid (10 μM; 1-5 days) 可降低 RANKL 刺激的 BMM 中 NFATc1 及其靶蛋白 (Integrin αV、c-Fos、CTSK) 的表达。 Roburic acid (10 μM; 25 h) 可减弱 RANKL 诱导的 BMMs 钙振荡。 Roburic acid (1-10 μM; 24 h) 可在 RAW264.7 细胞中抑制 RANKL 诱导的 NFATc1 活性。 Roburic acid (10-40 μM; 4 h) 可在 293-TNF Res (NF-κB) 细胞中抑制 TNF 诱导的 NF-κB 激活。 Roburic acid (0-20 μM; 48 h) 可抑制 HCT-116、HCT-15、HT29 和 Colo205 人结直肠癌细胞的活力,其 IC50 值分别为 3.90、4.77、5.35 和 14.54 μM。 Roburic acid (4-16 μM; 8 days) 可抑制人结直肠癌细胞 HCT-116 和 HCT-15 的集落形成。 Roburic acid (4-16 μM; 26 h) 可抑制人结直肠癌细胞系 HCT-116 和 HCT-15 的 DNA 合成。 Roburic acid (4-16 μM; 24 h) 可在人结直肠癌细胞 HCT-116 和 HCT-15 中诱导 G0/G1期细胞周期阻滞。 Roburic acid (4-16 μM; 24 h) 可在无血清培养基中处理 24 小时后诱导人结直肠癌细胞 HCT-116 和 HCT-15 发生细胞凋亡。 Roburic acid (8 μM) 可在人结直肠癌细胞 HCT-116 和 HCT-15 中抑制 TNF 诱导的 NF-κB 信号通路。 Roburic acid (8 μM; 4.5 h) 可抑制 TNF 诱导的人结直肠癌 HCT-116 和 HCT-15 细胞中p65的核转位。 Roburic acid (5-20 μM; 25 h) 以剂量依赖的方式抑制 LPS (MS-X54539) 诱导的 RAW264.7 细胞中 NO、iNOS 和 IL-6 表达,抑制 NF-κB p65 核转位。 Roburic acid (5-20 μM; 1.5 h) 剂量依赖性抑制 RAW264.7 细胞中 LPS 诱导的 IKKα/β、p38 和 JNK MAPK 磷酸化。
Real Time qPCR
| Cell Line: |
RANKL-stimulated bone marrow macrophages (BMMs) |
| Concentration: |
5 and 10 μM |
| Incubation Time: |
6 days |
| Result: |
Dose-dependently decreased the mRNA levels of osteoclast-related genes (c-Fos, Acp5, Nfatc1, Atp6v0d2, Ctsk, Mmp9) that were upregulated by RANKL. |
Western Blot Analysis
| Cell Line: |
RANKL-stimulated bone marrow macrophages (BMMs) |
| Concentration: |
10 μM |
| Incubation Time: |
10, 20, 30, 60 min (short-term); 1, 3, 5 days (long-term) |
| Result: |
Restricted TRAF6 expression, ERK1/2 phosphorylation, and IκB-α degradation in RANKL-stimulated BMMs. |
Western Blot Analysis
| Cell Line: |
RANKL-stimulated bone marrow macrophages (BMMs) |
| Concentration: |
10 μM |
| Incubation Time: |
1, 3, 5 days |
| Result: |
Boosted HO-1 protein expression that was downgraded by RANKL from Day 1 to 3.\nAttenuated the expression of NFATc1, Integrin αV, c-Fos, and CTSK in RANKL-stimulated BMMs. |
Cell Viability Assay
| Cell Line: |
HCT-116, HCT-15, HT29, Colo205 human colorectal cancer cell lines |
| Concentration: |
0, 1, 2, 4, 6, 8, 10, 15 and 20 μM |
| Incubation Time: |
48 h |
| Result: |
Inhibited cell viability in all tested cell lines with IC50 values of 3.90 μM (HCT-116), 4.77 μM (HCT-15), 5.35 μM (HT29), and 14.54 μM (Colo205). |
Cell Proliferation Assay
| Cell Line: |
HCT-116, HCT-15 human colorectal cancer cells |
| Concentration: |
4, 8 and 16 μM |
| Incubation Time: |
8 days |
| Result: |
Significantly inhibited colony formation in a concentration-dependent manner. |
Cell Proliferation Assay
| Cell Line: |
HCT-116, HCT-15 human colorectal cancer cells |
| Concentration: |
4, 8 and 16 μM; 10 μM (EdU) |
| Incubation Time: |
24 h (roburic acid treatment; 2 h EdU incubation) |
| Result: |
Markedly suppressed DNA synthesis in both cell lines. |
Cell Cycle Analysis
| Cell Line: |
HCT-116, HCT-15 human colorectal cancer cells |
| Concentration: |
4, 8 and 16 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly increased the percentage of G0/G1 phase cells and decreased the percentages of S and G2 phase cells in both cell lines in a concentration-dependent manner. |
Apoptosis Analysis
| Cell Line: |
HCT-116, HCT-15 human colorectal cancer cells |
| Concentration: |
4, 8 and 16 μM |
| Incubation Time: |
24 h (serum-free medium) |
| Result: |
Led to a significant, concentration-dependent increase in the number of Annexin V-FITC-positive (apoptotic) cells in both cell lines. |
Western Blot Analysis
| Cell Line: |
HCT-116, HCT-15 human colorectal cancer cells |
| Concentration: |
8 μM; 10 ng/mL (TNF) |
| Incubation Time: |
4 h (pretreatment; followed by TNF stimulation for indicated times) |
| Result: |
Inhibited TNF-induced phosphorylation of IKKα/β, IκBα, and p65, degradation of IκBα, and expression of NF-κB-target genes (XIAP, Mcl-1, Survivin, Cyclin D1, c-Myc) in both cell lines. |
Immunofluorescence
| Cell Line: |
HCT-116, HCT-15 human colorectal cancer cells |
| Concentration: |
8 μM; 10 ng/mL (TNF) |
| Incubation Time: |
4 h (pretreatment; 30 min TNF stimulation) |
| Result: |
Significantly inhibited TNF-induced p65 nuclear translocation in both cell lines. |
Cell Viability Assay
| Cell Line: |
RAW264.7 macrophage cells |
| Concentration: |
5, 10, 20 and 50 μM |
| Incubation Time: |
24 h |
| Result: |
Inhibited less than 20% of cell proliferation at concentrations up to 20 μM; showed greater inhibition at 50 μM relative to untreated cells. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated RAW264.7 macrophage cells |
| Concentration: |
5, 10 and 20 μM |
| Incubation Time: |
|
体内研究 (In Vivo) |
Roburic acid (5 mg/kg; i.v.; 共 4 次) 可对佐剂诱导性关节炎大鼠的类风湿性关节炎症状、炎症及骨侵蚀发挥中度改善作用。 Roburic acid (10 mg/kg; i.p.; 每两天一次共 7 周) 可通过改善骨小梁骨参数缓解去卵巢 (OVX) 诱导的小鼠骨丢失。 Roburic acid (5-10 mg/kg; i.p.; 每日一次共 18 天) 通过阻断 NF-κB 信号通路抑制异种移植小鼠的结直肠癌肿瘤生长,可显著降低肿瘤体积与重量。
| Animal Model: |
Sprague-Dawley (male, 180-220 g, adjuvant-induced arthritis model) |
| Dosage: |
5 mg/kg |
| Administration: |
i.v.; on days 17, 20, 23, 26 |
| Result: |
Slightly reduced paw swelling and arthritis score. Limited reduction in inflammatory cell infiltration and synovial hyperplasia. Moderated relief of cartilage and bone tissue disappearance; moderate reduction in spleen and thymus indices. Limited downregulation of IL-1β, IL-6, and TNF-α secretion in ankle joints; moderate reduction in osteoclast number. Limited increase in ALP expression, moderate lowering of RANKL/OPG ratio; moderate improvement in bone mineral density (BMD), limited reduction in trabecular separation (Tb.Sp), and moderate increase in trabecular bone thickness (Tb.Th). |
| Animal Model: |
C57BL/6J mice (10-week-old female, ovariectomized) |
| Dosage: |
10 mg/kg |
| Administration: |
i.p.; once every 2 days; 7 weeks |
| Result: |
Significantly increased trabecular bone parameters including bone volume/tissue volume (BV/TV), bone surface/tissue volume (BS/TV), trabecular number (Tb.N), and trabecular pattern factor (Tb.Pf) compared to the OVX group; Reduced bone deterioration observed via representative micro-CT images. |
| Animal Model: |
BALB/c nude (male, 5 weeks old, subcutaneous colorectal cancer xenograft model) |
| Dosage: |
5, 10 mg/kg |
| Administration: |
i.p.; once daily; 18 days |
| Result: |
Significantly decreased tumor volume and weight of HCT-116 and HCT-15 xenografts. Inhibited phosphorylation of p65 in tumor tissues. Promoted cleavage of Caspase3 in tumor tissues; suppressed protein expression of Bcl-xL, XIAP, and Cyclin D1 in tumor tissues. Downregulated expression of p-p65 and Ki-67 in treated tumors; increased level of cleaved Caspase3 in treated tumors. |
|
| 性状 |
固体 |
| 颜色 |
White to off-white |
| 分子量 |
440.70 |
| 分子式 |
C30H48O2 |
| CAS No. |
6812-81-3 |
| 别名 |
栎樱酸 |
| 体内实验配方 |
10% DMSO+90% Corn Oil: 2.5 mg/mL (5.67 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
4°C, sealed storage, away from moisture and light
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 33.33 mg/mL (75.63 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 2.2691 mL | 11.3456 mL | 22.6912 mL | 56.7279 mL | | 5 mM | 0.4538 mL | 2.2691 mL | 4.5382 mL | 11.3456 mL | | 10 mM | 0.2269 mL | 1.1346 mL | 2.2691 mL | 5.6728 mL | | 15 mM | 0.1513 mL | 0.7564 mL | 1.5127 mL | 3.7819 mL | | 20 mM | 0.1135 mL | 0.5673 mL | 1.1346 mL | 2.8364 mL | | 25 mM | 0.0908 mL | 0.4538 mL | 0.9076 mL | 2.2691 mL | | 30 mM | 0.0756 mL | 0.3782 mL | 0.7564 mL | 1.8909 mL | | 40 mM | 0.0567 mL | 0.2836 mL | 0.5673 mL | 1.4182 mL | | 50 mM | 0.0454 mL | 0.2269 mL | 0.4538 mL | 1.1346 mL | | 60 mM | 0.0378 mL | 0.1891 mL | 0.3782 mL | 0.9455 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|